OTCBB: ACTC has been issued a patent (no# 8,017,393) for a method for generating and expanding hemangioblast cells from human embryonic stem cells (hESCs) Read more…
The IMPACT-DCM clinical trial for ixmyelocel-T showed that treatment was well-tolerated and that efficacy observations were consistent Read more…
$47M raised through activity of 13, At-The-Market (ATM) offerings of common stock in Q2 of FY11. Read more…
Good morning! Read more…
End of Day, Cause and Effect, so what’s causing the rise or bounces? Read more…
The 6 W’s: Who, what, where, when, why and what of it… Read more…
Good morning! Read more…
End of Day, Cause and Effect, so what’s causing the rise or bounces? Read more…
The 6 W’s: Who, what, where, when, why and what of it… Read more…
Cellerant Therapeutics (CTI) has been awarded additional funding valued at $16.7M by the Biomedical Advanced Research and Development Authority (BARDA) Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.